Infectious bovine rhinotrachetis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
AssigneesNovaGene, Inc., Baylor College of Medicine
InventorsMalon Kit, Saul Kit, Haruki Otsuka
Life of this patent
Estimating the term…
Abstract
Infectious bovine rhinotracheitis virus (bovine herpesvirus type 1) mutants containing deletion and/or insertion mutations in a major viral glycoprotein gene, such that no antigenic polypeptides encoded by the viral gene are produced, vaccines for infectious bovine rhinotracheitis containing the same, methods for the production of the same and methods for use of the same. Animals vaccinated with these mutants do not develop antibodies to the viral glycoprotein and can be distinguished serologically from animals infected with infectious bovine rhinotracheitis virus field strains.
Claims58
A vaccine for infectious bovine rhinotracheitis disease comprising:
- (1) A pharmaceutially effective amount of an infectious bovine rhinotracheitis virus which fails to produce any antigenic IBRV gIII polypeptides as a result of a deletion, an insertion or both a deletion and an insertion in the IBRV gIII gene;
- and
- (2) A pharmaceutially acceptable carrier or diluent.
A vaccine for infectious bovine rhinotracheitis disease comprising:
- (1) a pharmaceutically effective amount of an infectious bovine rhinotracheitis virus which fails to produce any antigenic IBRV gIII polypeptides as a result of a deletion in the IBRV gIII gene produced by the process comprising:
- (a) Constructing a hybrid plasmid comprising a cloning vector and a DNA fragment of IBRV containing substantially all of the IBRV gIII gene flanking sequences thereof;
- (b) Deleting DNA sequences from the hybrid plasmid of step (a) such that less than substantially all of the IBRV gIII gene is present, while retaining IBRV DNA sequences adjacent to each side of the deletion;
- (c) Co-transfecting, in IBRV host cells, the hybrid plasmid of step (b) with infectious gIII.sup.+ IBRV DNA;
- and
- (d) Screening the progeny viruses obtained in step (c) so as to identify and produce IBRV mutants which fail to produce any antigenic IBRV gIII polypeptides as a result of a deletion in the IBRV gIII gene, and
- (2) A pharmaceutically acceptable carrier or diluent.
A vaccine for infectious bovine rhinotracheitis disease comprising:
- (1) a pharmaceutically effective amount of an infectious bovine rhinotracheitis virus which fails to produce any antigenic IBRV gIII polypeptides as a result of an insertion in the IBRV gIII gene produced by the process comprising:
- (a) Constructing a hybrid plasmid comprising a cloning vector and a DNA fragment of IBRV containing substantially all of the IBRV gIII gene and flanking sequences thereof;
- (b) Inserting a foreign DNA sequence into the hybrid plasmid of step (a) such that no antigenic IBRV gIII polypeptides are produced and such that IBRV DNA sequences adjacent to each side of the insertion are retained;
- (c) Co-transfecting, in IBRV host cells, the resulting hybrid plasmid of step (b) with infectious gIII.sup.+ IBRV DNA;
- and
- (d) Screening the progeny viruses obtained in step (c) so as to identify and produce IBRV mutants which fail to produce any antigenic IBRV gIII polypeptides as a result of an insertion in the IBRV gIII gene, and
- (2) A pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.